A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Conditions: Cancer; Neuroendocrine Tumors; NET; Adrenocortical Carcinoma; ACCIntervention: Drug: TKM-080301Sponsor: Tekmira Pharmaceuticals CorporationActive, not recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adrenocortical Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Neurology | Research | Study